Navigation Links
Diabetes Cure With Gene Therapy

A gene therapy developed by researchers has cured diabetes in mice by inducing cells in the liver to become beta cells that produce insulin and three other hormones. The researchers used NeuroD gene which induces the liver to produce cells that make insulin and hormones relating to pancreas. NeuroD partially cured diabetic mice, but when combined with beta cell growth factor, diabetes was completely cured. Also cells in liver produce glucagon, somostatin and pancreatic// polypeptide which are important in controlling insulin production and release. However one cannot claim, the treatment can directly be used in humans because of the virus used to take the gene into the cell. Researchers are expecting for more safer virus to taking the gene. The treatment has advantages over transplant of islet cells, the insulin producers in the pancreas, because it avoids the lifelong use of powerful immunosuppressive drugs and eliminates the need to find a compatible donor.
'"/>




Page: 1

Related medicine news :

1. Is Diabetes the Leading Cause of Kidney Failure in India
2. Diabetes and Depression often go hand-in-hand
3. Thirty minutes of work up per day reduces the risk of Diabetes
4. Diabetes on the rise
5. Irregular Periods Linked to Diabetes
6. Cinnamon combats Diabetes
7. Good News For Women With Gestational Diabetes
8. Processed Meat, Diabetes connection Found
9. Pancreatic Cancer may be linked to Diabetes
10. Gestational Diabetes linked to Chromosomal defici
11. A way to slow the progression of Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Diabetes Cure With Gene Therapy

(Date:8/28/2008)... based in the Northeast region with more hires,pla...ARRISBURG, Pa., Aug. 28 /PRNewswire-USNewswire/ --...ed a Patient Safety Liaison for the,Northeast regi...e,Pennsylvania Patient Safety Reporting System (PA...izens., "Last year in focus groups with Pennsylva...
(Date:8/28/2008)...ke risk by 67%, but patients and doctors say drug ...(HealthDay News) -- Only 40 percent of patients wi...roke, who did suffer a stroke were taking the anti...mong those taking warfarin, 75 percent weren,t get...dditional 25 percent were taking medications that ...
(Date:8/28/2008)... Leading dermatology company serves growing prof... Palo Alto, CA (PRWEB) August 28, ...capital firm, today announced that together with M...is leading a Series A round of financing for Profe...tly invested $15.5 million in the round. Profex, a...
(Date:8/28/2008)...g. 28 /PRNewswire/ -- Guava Technologies, Inc.,ann...n Control Group to,provide drug discovery research...es. This non-exclusive agreement is a key componen...logies. The initiative is a direct,response to a v...ogy to,support higher throughput research in a com...
Breaking Medicine News(10 mins):Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 2Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 3Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 3Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 2Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 3
...owing evidence of a link between developing amyotr... Gehrig's disease and military service. This is a .... More research is needed as there have been very ...the disease and military service as mentioned in ...
...ation, or the Deutsche Forschungsgemeinschaft (DFG...enies access to new stem cell banks. In a stateme...n urgent need of revision.''Due to the key date re...d in the Stem Cell Act of 2002, German researchers...
...dmitted to Escorts Hospital and Research Centre he...condition //is "absolutely stable". "Mr. Pawar wa...is no problem other than stress and exhaustion. A ... his condition," Naresh Trehan, executive director...
... up their appointment for breast cancer screening ...ntment.// A report has shown that out of 79000 wo...ss than 60,000 women actually turned up for the ex...d of BreastCheck said 'It's an unusual service in ...
Other Medicine News:Health News:Link Shown Between Military Service And Risk For ALS 2Health News:Link Shown Between Military Service And Risk For ALS 3Health News:German Scientists Call For Review Of Stem Cell Act 2
(Date:8/26/2008)...- The Oregon Tourism Commission,launched its new f...Program,(Q Care) this week on http://www.OregonQC...eated to support the tourism and,hospitality indus...izing,the importance of quality customer service, ...esources to better serve Oregon,s visitors., "We,...
(Date:8/26/2008)...-- Semafore Pharmaceuticals Inc.,announced data pr...argeted,Therapies in Cancer in Washington, D.C., s...lar-targeted PI3 kinase (PI3K) inhibitor SF1126, b...part of a very powerful pathway, the PI3/AKT /mTOR...in cancer. Studies have shown that by,inhibiting t...
(Date:8/26/2008)... safely six weeks following surgical,treatment, R...Six weeks following,bunion surgery, most patients,...back behind the wheel of a car again. A study publ...one and Joint Surgery ( http://www.jbjs.org/ ),als...ents who underwent a,first metatarsal osteotomy (a...
(Date:8/26/2008)... -- Cambridge Research &,Instrumentation, Inc. (CR...Vivo Imaging System. The new system incorporates C...the entry-level instrument of choice for in,vivo f....com/cgi-bin/prnh/20080826/NETU054 ), FLEX techn...s unique,solid-state tunable optics that for the f...
Breaking Medicine Technology:Oregon Tourism Commission Unveils New Online Customer Service Training Program 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3Braking After Bunion Surgery 2Braking After Bunion Surgery 3CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price 2Fuwei Films to Convene Annual Shareholders Meeting On December 21 in New York City 8109 1Fuwei Films to Convene Annual Shareholders Meeting On December 21 in New York City 8109 2Fuwei Films to Convene Annual Shareholders Meeting On December 21 in New York City 8109 3INVEGA 28TM 29 Shows Favorable Long Term Safety Profile in a One Year Study of Patients With Schizophrenia 8107 1INVEGA 28TM 29 Shows Favorable Long Term Safety Profile in a One Year Study of Patients With Schizophrenia 8107 2INVEGA 28TM 29 Shows Favorable Long Term Safety Profile in a One Year Study of Patients With Schizophrenia 8107 3INVEGA 28TM 29 Shows Favorable Long Term Safety Profile in a One Year Study of Patients With Schizophrenia 8107 4INVEGA 28TM 29 Shows Favorable Long Term Safety Profile in a One Year Study of Patients With Schizophrenia 8107 5INVEGA 28TM 29 Shows Favorable Long Term Safety Profile in a One Year Study of Patients With Schizophrenia 8107 6Network Health Awards Contract to HMS for Coordination of Benefits 8105 1Network Health Awards Contract to HMS for Coordination of Benefits 8105 2Kaiser Permanente to Host 30th Annual Diversity Conference 2152 1Kaiser Permanente to Host 30th Annual Diversity Conference 2152 2Kaiser Permanente to Host 30th Annual Diversity Conference 2152 3
... Safety and Single-Agent Activity Support Developm...Glioblastoma Multiforme, ROCKVILLE, Md., June 05, ...clinical-stage pharmaceutical company developing,t...matory diseases,announces the presentation of res... NCD (2ME2) in patients with glioblastoma,multifor...
... FLEMINGTON, N.J.--(BUSINESS WIRE)--Jun 5, 2007 - ...aceutical company developing,oral spray formulatio... announced that its two clinical studies comparing...t their primary,pharmacokinetic (PK), pharmacodyna...re currently marketed as Ambien(R), a leading,drug...
Other Medicine Technology:Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 2Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 3Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 4NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 2NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 3NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 4NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 5NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 6NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 7
The perfect solution for quick, easy reference on the wards, on rounds, in the office, and at the bedside. See vital information on specific signs and symptoms, diagnostic tests, and the gamut of neu
...ews enable all those involved with healthcare deci...ence in their field of interest - a challenge whic...ce increases. Cochrane Reviews solve this problem ... continually updated evidence-based medical inform...
...ed in the Clinical Neurology 2007 are: evaluation ...inating disease including MS and Guillain-Barre, c...ders (tics, Tourette, dystonia..), tremors, Parkin...aches, coma, cervical spine problems, low back pai...
Cardiology eText is a concise yet complete eTextbook of standard diagnosis and treatment recommendations for cardiovascular disease. In addition to the Redi-Reference - Cardiology eText electronic te
Medicine Products: